ACM
FULC icon

ADAR1 Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

ADAR1 Capital Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-65,000
Closed -$735K – 319
2025
Q4 		$735K Sell
65,000
-10,000
-13% -$102K 0.05% 161
2025
Q3 		$690K Buy
+75,000
New +$543K 0.06% 119
2024
Q4 		– Sell
-15,000
Closed -$53.5K – 249
2024
Q3 		$53.5K Sell
15,000
-5,000
-25% -$37.1K 0.01% 214
2024
Q2 		$124K Buy
+20,000
New +$152K 0.02% 160

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ADAR1 Capital Management's FULC Position: Q2 2026 in Review

ADAR1 Capital Management increased its Fulcrum Therapeutics (FULC) stake by 1,099% in Q2 2026, buying an estimated $8.73M and bringing the position to 1,565,029 shares worth $5.73M. The position accounts for 0.26% of the portfolio, ranked #89.

ADAR1 Capital Management first reported a position in FULC in Q4 2023 and has held it in 11 quarters since. The position peaked at $14.2M in Q4 2025. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • ADAR1 Capital Management held 1,565,029 shares of Fulcrum Therapeutics worth $5.73M as of Q2 2026.
  • ADAR1 Capital Management bought 1,434,469 Fulcrum Therapeutics shares in Q2 2026, an estimated $8.73M.
  • Fulcrum Therapeutics made up 0.26% of ADAR1 Capital Management's portfolio in Q2 2026, its #89 holding.
  • ADAR1 Capital Management first reported a position in Fulcrum Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • ADAR1 Capital Management's Fulcrum Therapeutics position peaked at $14.2M in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.